Mineralys CMO James Ferguson Receives RSUs and Option Award

What Happened

• James J. Ferguson III, Chief Medical Officer of Mineralys Therapeutics (MLYS), received two equity awards on August 10, 2026: 102,400 restricted stock units (RSUs) and a 135,000-share derivative award. Both awards were granted for no cash consideration (reported price $0.00), representing potential ownership of up to 237,400 shares if fully vested/settled.
• These are grants/awards (not open-market purchases or sales) and therefore are routine compensation rather than a direct market purchase or sale.

Key Details

• Transaction dates and prices: 2026-08-10 — 102,400 RSUs @ $0.00; 2026-08-10 — 135,000 derivative shares @ $0.00.
• Shares owned after the transaction: Not disclosed in the information provided in this summary.
• Vesting / footnotes:
  • RSUs (102,400): vest in annual installments over four years — 1/4 of the RSUs vest on each one‑year anniversary of the grant (Footnote F1).
  • Derivative (135,000): described with a vesting schedule of 25% on the first anniversary and the remainder in 36 substantially equal monthly installments (Footnote F2), consistent with a typical stock option or time‑based equity award.
• Filing timeliness: Form 4 filed 2026-08-12 reporting the 2026-08-10 grants — appears to be filed within the normal two-business-day window (timely).

Context

• These awards are compensation grants (not immediate purchases or sales). RSUs convert to shares only as they vest; the derivative award appears to be subject to a multi-year vesting schedule, so the shares are not immediately tradable.
• Such awards are common for executive compensation and do not by themselves indicate buying or selling intent in the public market.